Abstract
AIM: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of concurrent chemoradiotherapy and cetuximab in patients with non-resectable locally advanced esophageal cancer.
PATIENTS AND METHODS: Escalating doses of oxaliplatin every second week and daily tegafur/uracil were given concurrently with radiotherapy, 59.4 Gy in 33 fractions. Cetuximab was given on day 15 (400 mg/m(2)) and weekly (250 mg/m(2)) during radiotherapy. Fixed doses of oxaliplatin (130 mg/m(2)) and tegafur/uracil (300 mg/m(2)) were administered before, and after radiotherapy.
RESULTS: Eleven patients were included in the study; two were excluded due to allergic reactions to cetuximab. In DL2 (tegafur/uracil 300 mg/m(2), oxaliplatin 30 mg/m(2)) two grade 3/4 fistula and one grade 3 neuropathy were observed. Six patients were enrolled in DL1 (tegafur/uracil 150 mg/m(2)/, oxaliplatin 30 mg/m(2)) with no DLTs. Four out of 9 patients had complete response.
CONCLUSION: Concomitant chemoradiotherapy and cetuximab had significant activity. DL1 was established as the MTD.
| Original language | English |
|---|---|
| Journal | Anticancer Research |
| Volume | 32 |
| Issue number | 9 |
| Pages (from-to) | 4019-23 |
| Number of pages | 5 |
| ISSN | 0250-7005 |
| Publication status | Published - Sept 2012 |
Keywords
- Adult
- Aged
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
- Cetuximab
- Chemoradiotherapy
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Esophageal Neoplasms
- Female
- Humans
- Male
- Middle Aged
- Organoplatinum Compounds
- Tegafur
- Uracil
- Clinical Trial, Phase I
- Journal Article
- Research Support, Non-U.S. Gov't
